ClinicalTrials.gg
CompletedNCT05954169Updated Jul 11, 2024

Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

A Phase 1 interventional study of SHR4640 in Hyperuricemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing ruzinurad in Hyperuricemia — 1 open to participants now, 1 under way, none of them phase 3. ruzinurad · Hyperuricemia.

Enrollment
11th of 11
16 · median 34
Started
2023
with 1 other
Phase 1
8 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
10 of 11
Jiangsu HengRui Medicine Co., Ltd.

Among the 11 studies testing ruzinurad in Hyperuricemia, this one is the 11th largest by enrollment, is one of 2 that started in 2023, is one of 8 in phase 1, and was the 8th registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

1 of the 11 studies testing ruzinurad in Hyperuricemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About ruzinurad

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ruzinurad in Hyperuricemia, or all of them as a file.
02

Study summary

This study aimed to evaluate the pharmacokinetics, pharmacodynamics, and safety of SHR4640 tablets in subjects with moderate renal insufficiency and healthy subjects, and to explore the relationship between renal function (e.g., eGFR) and SHR4640 pharmacokinetic and pharmacodynamic parameters.

03

Conditions studied

  • Hyperuricemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Moderate renal impaired subjects:

  1. Able and willing to provide a written .
  2. 18 years to 65 years (inclusive).
  3. should be between 18 and 35 kg/m2 (inclusive).
  4. should be between 30 and 59 mL/min/1.73 m2 (inclusive).
  5. The renal function status is stable, and the results of two eGFR tests during the screening period (at least 3 days apart, but within 14 days) should be within ±25%.
  6. If subjects with underlying diseases required drug treatment, the dose needs to be kept stable during study.

Healthy subjects:

  1. Able and willing to provide a written informed consent.
  2. 18 years to 65 years (inclusive).
  3. Body mass index should be between 18 and 35 kg/m2 (inclusive).
  4. eGFR should be ≥ 90 and \< 130 mL/min/1.73 m2.
  5. The renal function status is stable, and the results of two eGFR tests during the screening period (at least 3 days apart, but within 14 days) should be within ±25%.

Exclusion criteria

Exclusion Criteria:

-

Moderate renal impaired subjects:

  1. Pregnant or nursing women.
  2. No 2 weeks before screening or until one week after SHR4640 administration.
  3. Average daily alcohol consume more than 14g for female or more than 28g for male within 1 month before screening, or baseline alcohol screening is positive.
  4. Smokers (average daily smoking of 10 cigarettes or more in the 3 months before screening).
  5. Subject with a history of substance abuse and drug abuse.
  6. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
  7. The investigators or relevant staff of the research centers or others directly involved in the study.
  8. 2 weeks before SHR4640 administration sUA level ≥480 μmol/L.
  9. and/or aspartate aminotransferase>2×, alkaline phosphatase (ALP)>2.5×ULN.
  10. Positive result for surface antigen.
  11. Positive result for (HIV), virus antibody or syphilis antibody.
  12. White blood cell \< 3.0×109/L, and/or \<80 g/L, and/or \<80×109/L.
  13. 12-lead (ECG) showed abnormal and .
  14. History of to SHR4640 or its analogues.
  15. History or suspected crystals or stones in the urinary system during the screening period of B-ultrasound.
  16. History of been diagnosed with acute kidney injury in the past or screening period.
  17. History of kidney transplantation.
  18. Renal dialysis required during the study.
  19. Urinary incontinence or anuria (eg\< 100 mL/d).
  20. Cardiovascular, neuropsychiatric, respiratory, digestive tract, endocrine and other systemic diseases within 1 year before screening, which were judged to be serious by the investigators.
  21. Have grade III or IV congestive heart failure ( classification) or myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage or within 1 year of screening, and other cardiovascular and cerebrovascular events leading to hospitalization.
  22. History of active peptic ulcer within 1 year before screening, previous history of active gastrointestinal bleeding, gastrointestinal perforation, history of inflammatory bowel disease, or active peptic ulcer at screening.
  23. Have a malignant tumor, or have a history of malignant tumor within 5 years before screening.
  24. SBP≥180 mmHg and/or DBP ≥110 mmHg.
  25. Had undergone major surgery within 3 months prior to screening, or have not recovered from surgery, or plan major surgery during the study.
  26. Received the last dose of a study drug (or treatment with a medical device) within 3 months or 5 T1/2 (whichever is longer) of the screening or are currently participating in another study of a study drug (or medical device).
  27. Blood donation within 1 month before screening; Or patients with trauma or major surgical procedures who donated blood or lost blood ≥400 mL in the 3 months prior to screening.
  28. Has unsuitable venous for blood sampling.
  29. Use of any of the following, unless agreed as nonclinically relevant by the Investigator and the Sponsor:
  1. Use of any over the-counter, nutraceuticals, or prescription medications that might interfere with the absorption, distribution, metabolism, or excretion of SHR4640 (proton-pump inhibitor, fluconazole, indomethacin, ranitidine, flurbiprofen, probenecid, aprepitant, etc.) within 2 weeks of screening.
  1. Unstable dosage of urate-lowering drugs within 6 weeks of Day 1. 3) Diuretics within 2 weeks of Day 1. 4) Aspirin in excess of 100 mg daily or unstable dose within the 2 weeks of Day 1.
  1. Unstable dosage of antihypertensive, lipid-lowering and hypoglycemic drugs within 2 weeks of Day 1.
  1. Have received or been exposed to other or live attenuated vaccines within 3 months prior to Day 1, or who plan to receive live vaccines or live attenuated vaccines during the study.
  1. Consumes grapefruit and/or poppy seed within 48 hours before SHR4640 administration.
  1. Taken prescription drugs, over-the-counter drugs, herbal medicines or food supplements other than drugs for the treatment of renal insufficiency and other concomitant diseases within 2 weeks before Day 1.

Healthy subjects:

  1. Pregnant or nursing women.
  2. No birth control 2 weeks before screening or until one week after SHR4640 administration.
  3. Average daily alcohol consume more than 14g for female or more than 28g for male within 1 month before screening, or baseline alcohol screening is positive.
  4. Smokers (average daily smoking of 10 cigarettes or more in the 3 months before screening).
  5. Subject with a history of substance abuse and drug abuse.
  6. The investigators determined that other conditions were inappropriate for participation in this clinical trial.
  7. The investigators or relevant staff of the research centers or others directly involved in the study.
  8. 2 weeks before SHR4640 administration sUA level ≥420 μmol/L.
  9. Laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function) during the screening period were abnormal and the investigators determined that they were clinically significant.
  10. Positive result for hepatitis B surface antigen.
  11. Positive result for human immunodeficiency virus (HIV), hepatitis C virus antibody or syphilis antibody.
  12. 12-lead electrocardiogram (ECG) showed abnormal and clinically significant.
  13. History of hypersensitivity to SHR4640 or its analogues.
  14. History or suspected crystals or stones in the urinary system during the screening period of B-ultrasound.
  15. History of been diagnosed with chronic or acute kidney injury in the past or screening period. History of kidney transplantation.
  16. Cardiovascular, neuropsychiatric, respiratory, digestive tract, endocrine and other systemic diseases within 1 year before screening, which were judged to be serious by the investigators.
  17. Have a malignant tumor, or have a history of malignant tumor within 5 years before screening.
  18. SBP>140 mmHg or \<90 mmHg and/or DBP >90 mmHg or \<60 mmHg.
  19. Had undergone major surgery within 3 months prior to screening, or have not recovered from surgery, or plan major surgery during the study.
  20. Received the last dose of a study drug (or treatment with a medical device) within 3 months or 5 T1/2 (whichever is longer) of the screening or are currently participating in another study of a study drug (or medical device).
  21. Blood donation within 1 month before screening; Or patients with trauma or major surgical procedures who donated blood or lost blood ≥400 mL in the 3 months prior to screening.
  22. Has unsuitable venous for blood sampling.
  23. Use of any of the following, unless agreed as nonclinically relevant by the Investigator and the Sponsor:
  1. Use of any over the-counter, nutraceuticals, or prescription medications that might interfere with the absorption, distribution, metabolism, or excretion of SHR4640 (proton-pump inhibitor, fluconazole, indomethacin, ranitidine, flurbiprofen, probenecid, aprepitant, etc.) within 2 weeks of screening.
  1. Use of urate-lowering drugs within 6 weeks of Day 1. 3) Have received or been exposed to other live vaccines or live attenuated vaccines within 3 months prior to Day 1, or who plan to receive live vaccines or live attenuated vaccines during the study.
  1. Consumes grapefruit and/or poppy seed within 48 hours before SHR4640 administration.
  1. Taken any prescription drugs, over-the-counter drugs, herbal medicines or food supplements within 2 weeks before Day 1.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment group A in moderately renal insufficiency subjects

    Drug: SHR4640

  • Experimental
    Treatment group B in healthy subjects

    Drug: SHR4640

Interventions

06

What researchers measure

Primary outcomes

  1. PK parameters of SHR4640: Cmax

    Time frame: 0 hour to 72 hour after administration

  2. PK parameters of SHR4640: AUC0-t

    Time frame: 0 hour to 72 hour after administration

  3. PK parameters of SHR4640: AUC0-inf

    Time frame: 0 hour to 72 hour after administration

Secondary outcomes

  1. PK parameters of SHR4640: Tmax

    Time frame: 0 hour to 72 hour after administration

  2. PK parameters of SHR4640: t1/2

    Time frame: 0 hour to 72 hour after administration

  3. PK parameters of SHR4640: CL/F

    Time frame: 0 hour to 72 hour after administration

  4. PK parameters of SHR4640: Vz/F

    Time frame: 0 hour to 72 hour after administration

  5. Amount of SHR4640 excreted in urine (Ae0-72h)

    Time frame: 0 hour to 72 hour after administration

  6. Serum uric acid concentration

    Time frame: 0 hour to 72 hour after administration

  7. Amount of uric acid excreted in urine

    Time frame: 0 hour to 72 hour after administration

  8. Adverse events

    Time frame: from ICF signing date to approximate day 8

07

Study locations

1 site
  • The Second Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 511447, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jul 2024, 10 months.

Of 29 industry-sponsored phase 1 interventional studies under Hyperuricemia, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 10 months is above that.

Counting every sponsor, half of 31 studies reached it within 6 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2023
First posted
Jul 20, 2023
StartActual
Aug 7, 2023
Primary completionActual
Jul 1, 2024
CompletionActual
Jul 1, 2024
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05954169
Responsible party
Sponsor
First posted
Jul 20, 2023
Start date
Aug 7, 2023
Primary completion
Jul 1, 2024
Completion
Jul 1, 2024
Last update
Jul 11, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruzinurad

Start the discussion